In the mid-2000s, when Pharmaceutical Commerce was founded, the editors and writers spent a lot of time talking about how state-of-the-art computing and data analysis would revolutionize medicine. The thought was that as more patient data was collected and analyzed […]
Read MoreA couple years ago, all the chatter about meeting the requirements of the Drug Supply Chain Security Act (DSCSA) in the US, and the Falsified Medicines Directive in the EU, was getting manufacturers onboard with putting serial codes on their […]
Read MoreWelcome to our 5th annual report on patient support / hub services. Pharmaceutical Commerce has been highlighting this part of the life-sciences service universe for two reasons: one trivial and one profound. The trivial reason is that the topic fits […]
Read MoreAfter all the arguing over drug prices, the cost of healthcare and many of the related disputes, most Americans take comfort from the fact that the nation as a whole is getting healthier and living longer. But—at this time—that is […]
Read MoreA good way to get vendors involved in pharma cold-chain services and equipment looking sideways is to ask them to provide the data they collect during shipments and deliveries. In the frictionless, IoT (Internet of Things) world we are entering, […]
Read MoreCountless Hollywood movies present the film’s heroes trapped in some dire circumstance, with hope fading, only to be saved by the arrival of reinforcements/allies/best buddies at the very end. Something of the same scenario is playing out with blockchain as […]
Read MoreFor the first time ever, adults with primary progressive multiple sclerosis, an aggressive form of multiple sclerosis, have a treatment. The intravenous drug, Ocrevus (ocrelizumab), approved by FDA last March, is the first treatment to slow the progression of PPMS […]
Read MoreFor many years, pharma companies shipping temperature-sensitive products have relied on temperature loggers to monitor the condition of the drugs while in transit. These devices have become cheap, reliable and ubiquitous. But if your organization relies solely on these devices […]
Read MoreEver since Scott Gottlieb took over as commissioner at FDA, he has sounded a constant theme of accelerating the approval of generic drugs as a way for FDA to rein in rising drug costs. In mid-October, FDA issued more than […]
Read MoreThe pharma industry is well along in a shift from traditional mass-market drugs to specialties, which now represent 43% of net drug spending (invoice price less discounts), and which has doubled its proportion in overall drug spending over the past […]
Read More